CADL vs STLN: fair value comparison
Candel Therapeutics, Inc. and The Oncology Institute, Inc. · Updated 2026-10-19
CADL has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. STLN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, STLN currently ranks higher by quality score.
| CADL | STLN | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $8.19 | $6.43 |
| 12-month range | $4.42–$13.75 | $2.38–$7.05 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #283 of 301 Healthcare | #281 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | — |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Uptrend |
| 52-week position | The lower-middle quarter | The top quarter |
Full single-stock breakdowns: CADL fair value analysis · STLN fair value analysis